Three blood cancer organizations have appealed a NICE draft guidance, which could make the therapy unavailable for mantle ...

EGFR drug ALX2004 and evorpacept, which recently showed activity with Jazz's Ziihera in CD47- and HER2-positive breast cancer.

The agency previously declined to approve the application for UX111, citing issues related to chemistry, manufacturing, and controls (CMC).

The nonprofit biotech recently licensed the gene therapy from Boston Children's Hospital and plans to bring it to low- and middle-income countries.

After a young woman develops mobility and speech issues, her grandmother seeks help from her genetic counselor, who flags a ...

UniQure had planned to seek accelerated approval for AMT-130 early 2026, but then said its plans were stalled after ...

The company, founded by UC Berkeley scientists including Jennifer Doudna, is preparing to test its lead candidate STX-1150 in ...

NEW YORK – A buzzy San Francisco-based biotech called Siren will test its adeno-associated virus (AAV) gene therapy and cytokine immunotherapy mashup for the first time in humans, the company said ...

The panel of four proteins, developed by Penn and Mayo researchers within an NCI project, is currently undergoing prospective ...

Sales rose 2 percent overall in 2025, driven by the strong performance of several oncology drugs, including greater uptake of ...

NEW YORK – Revolution Medicines on Thursday said it started treating patients with RAS G12V-mutated solid tumors in a Phase I trial of its RAS inhibitor RMC-5127. In the trial, Revolution will enroll ...

Researchers explored why only 40 percent of patients responded to Amgen's Imdelltra using TellBio's liquid biopsy test and ...